Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 24:12:925818.
doi: 10.3389/fonc.2022.925818. eCollection 2022.

Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm

Alana L Keller  1 , Daniel W Sherbenou  1   2 , Peter A Forsberg  1   2 , Tomer M Mark  1   2
Affiliations
Review

Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm

Alana L Keller et al. Front Oncol. .

Abstract

Multiple myeloma is an incurable hematologic malignancy. The typical disease course for myeloma patients is characterized by initial response to treatment followed by eventual development of resistance. Subsequent cycles of remission and relapse proceed as long as patients have new lines of therapy available to them. This reality has prompted development of many novel immunotherapeutics. Many of these drugs exploit the cytotoxic capabilities of the patients' own T cells, effectively redirecting them to myeloma cells that are otherwise evading immune attack. Approaches including CAR T cell therapy and bispecific antibodies have displayed impressive efficacy in clinical trials for myeloma patients. This review examines the different approaches that utilize T cells in multiple myeloma therapy and investigates the benefits and risks of these exciting new strategies.

Keywords: B cell maturation antigen; CAR T cell therapy; T cells; bispecific antibodies; immunotherapy; myeloma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. American Cancer Society . Key Statistics About Multiple Myeloma. Chicago, IL: American Cancer Society; (2021). Available at: https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html.
    1. Munshi N, Tricot G, Barlogie B. Plasma Cell Neoplasms. In: DeVita J VT, Hellman S, Rosenberg S, editors. Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkons; (2001). p. 2465–99.
    1. Kyle R, Rajkumar S. Multiple Myeloma. Blood (2008) 111(6):2962–72. doi: 10.1182/blood-2007-10-078022 - DOI - PMC - PubMed
    1. Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. . Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol (2018) 4(9):1221–7. doi: 10.1001/jamaoncol.2018.2128 - DOI - PMC - PubMed
    1. Alexanian R, Bergsagel D, Migliore P, Vaughn W, Howe C. Melphalan Therapy for Plasma Cell Myeloma. Blood (1968) 31(1):1–10. doi: 10.1182/blood.V31.1.1.1 - DOI - PubMed